Pfizer Inc. and Johnson & Johnson said Monday they are ending development of an intravenous formulation of a drug to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment